Post-earnings recap
Reported
Wed, May 5, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report showed that 10X Genomics Inc exceeded expectations on EPS, which is a positive sign for the company. However, the stock still fell by 1.08%, likely due to the lack of revenue figures and guidance. Investors may be cautious as they await more detailed financial metrics in future reports.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.11 | N/A | +55.65% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed confidence in their product pipeline and market position. They acknowledged the competitive landscape but emphasized their commitment to growth.
Management highlighted strong demand for their products despite ongoing market challenges.
They noted that they are focused on innovation and expanding their customer base.